Atherosclerotic cardiovascular disease
ASCVD · CVRM · 6 drugs · 6 indications
Coronary artery disease, stroke, peripheral artery disease.
Competitive Landscape (6 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Pelacarsen | NVS | Lp(a) reduction | Antisense oligonucleotide | SC | PHASE3 |
| MariTide | AMGN | GLP-1 agonist / GIP antagonist (bispecific) | Antibody-peptide conjugate | SC | PHASE3 |
| Olpasiran | AMGN | siRNA targeting LPA (Lp(a)) | siRNA | SC | PHASE3 |
| Brilinta | AZN | P2Y12 inhibitor | Small molecule | ORAL | APPROVED |
| Repatha | AMGN | PCSK9 inhibitor (monoclonal antibody) | Monoclonal antibody | SC | APPROVED |
| Praluent | REGN | PCSK9 inhibitor (monoclonal antibody) | Monoclonal antibody | SC | APPROVED |
Indications (6)
ASCVD CV risk reduction (ODYSSEY Outcomes)
Hyperlipidemia (primary prevention)
Hyperlipidemia (secondary prevention)
Elevated Lp(a) with ASCVD
Upcoming Catalysts
MariTide - Obesity - Ph2 Part 2 - Maintenance/Quarterly Dosing DataCLINICAL
AMGNH1 2026
Repatha - Primary Prevention - VESALIUS-CV Subgroups at ACCCLINICAL
AMGNMarch 2026
Pelacarsen - Lp(a) CV Prevention - Ph3 - Topline (HORIZON)CLINICAL
NVSH1 2026
MariTide - T2D + Obesity - Ph3 - Topline (MARITIME-2)CLINICAL
AMGNEarly 2027
MariTide - Obesity - Ph3 - Topline (MARITIME-1)CLINICAL
AMGNEarly 2027
MariTide - Obesity - BLA FilingREGULATORY
AMGN2027-2028
Olpasiran - Elevated Lp(a) - OCEAN(a)-Outcomes CVOTCLINICAL
AMGN2027+
MariTide - HFpEF - Ph3 - Outcomes (MARITIME-HF)CLINICAL
AMGN2028+
Data from Supabase · Updated 2026-03-24